-
Quidel Corp. (QDEL) PT Lowered to $55 at Raymond James
-
Quidel Corp (QDEL) Tops Q2 EPS by 12c ; Offers Guidance
-
Nephron Downgrades Quidel Corp. (QDEL) to Hold
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Citi on Quidel Corp. (QDEL): 'Savanna Discontinued; Molecular Strategy Pivots with Plans to Acquire LEX'
-
QuidelOrtho (QDEL) to acquire full ownership of LEX Diagnostics, announces strategy to accelerate growt
-
Jefferies Upgrades Quidel Corp. (QDEL) to Buy
-
Quidel Corp (QDEL) Tops Q1 EPS by 13c, provides guidance
-
QuidelOrtho (QDEL) launches Results Manager system, an informatics solution
-
Quidel Corp. (QDEL) PT Raised to $44 at Jefferies
-
Quidel Corp (QDEL) Tops Q4 EPS by 5c, provides guidance
-
QuidelOrtho (QDEL) Announces Preliminary Unaudited Revenue for Fourth Quarter 2024
-
Citi Upgrades Quidel Corp. (QDEL) to Buy
-
QuidelOrtho (QDEL) Announces Appointment of Two Independent Directors to its Board
-
Jefferies Starts Quidel Corp. (QDEL) at Hold
-
QuidelOrtho (QDEL) Prices 8.26M Share Offering by Selling Stockholders
-
QuidelOrtho (QDEL) Files for 8.26M Share Offering by Selling Stockholders
-
Quidel Corp (QDEL) Tops Q3 EPS by 58c, provides guidance
-
QuidelOrtho (QDEL) Appoints Jonathan Siegrist as Head of R&D and CTO
-
UBS Resumes Quidel Corp. (QDEL) at Neutral
-
Craig-Hallum Upgrades Quidel Corp. (QDEL) to Buy
-
QuidelOrtho (QDEL): VITROS Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.
-
Quidel Corp. (QDEL) PT Lowered to $44 at Citi
-
Quidel Corp (QDEL) Tops Q2 EPS by 16c, Beats on Revenue
-
Avantor (AVTR) to Join S&P MidCap 400; QuidelOrtho & Schneider National (QDEL) to Join S&P SmallCap 600
-
Life Science Tools & Diagnostics stocks: Q2 earnings preview

